SCHEMBL4523592

SCHEMBL4523592

Cc1cccc(OC(=S)N(C)C)c1C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.46
POLB P06746 2/20 0.45
ALDH1A1 P00352 5/20 0.40
HTR1B P28222 1/20 0.39
TRPA1 O75762 1/20 0.38
ATM Q13315 1/20 0.38
RAB9A P51151 3/20 0.37
NPC1 O15118 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
RECQL P46063 1/20 0.37
NCEH1 Q6PIU2 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
GAA P10253 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13158912 0.85 ALDH1A1 (0.39) MAPTPOLBALDH1A1ATMRAB9A
SCHEMBL27794544 0.79 POLB (0.49) MAPTPOLBALDH1A1HTR1BTRPA1
SCHEMBL7296849 0.78 CA12 (0.43) MAPTPOLBALDH1A1RAB9ANPC1
SCHEMBL25571686 0.78 NCEH1 (0.60) MAPTPOLBRAB9ANPC1NCEH1
SCHEMBL28410249 0.77 POLB (0.51) MAPTPOLBALDH1A1HTR1BTRPA1
SCHEMBL9869695 0.74 POLB (0.49) MAPTPOLBALDH1A1HTR1BTRPA1
SCHEMBL7281303 0.74 CA12 (0.47) MAPTPOLBALDH1A1RAB9ANPC1
SCHEMBL24813703 0.73 TP53 (0.48) MAPTPOLBALDH1A1ATMRAB9A
SCHEMBL3338632 0.73 SLC6A2 (0.38) MAPTPOLBALDH1A1TRPA1RAB9A
SCHEMBL1803105 0.72 POLB (0.59) MAPTPOLBALDH1A1HTR1BTRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090299074-A1 BENZO[b]THIOPHEN DERIVATIVES AND PROCESS FOR THEIR PRODUCTION TEIJIN PHARMA LIMITED (JP) 2009-12-03 US disclosed
US-20090299074-A1 BENZO[b]THIOPHEN DERIVATIVES AND PROCESS FOR THEIR PRODUCTION TEIJIN PHARMA LIMITED (JP) 2009-12-03 US disclosed
US-20090299074-A1 BENZO[b]THIOPHEN DERIVATIVES AND PROCESS FOR THEIR PRODUCTION TEIJIN PHARMA LIMITED (JP) 2009-12-03 US disclosed
EP-1947097-A1 BENZOÝb¨THIOPHEN DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF Teijin Pharma Limited (JP) 2008-07-23 EP disclosed
JP-2007145827-A BENZO[B]THIOPHENE DERIVATIVE AND PRODUCTION METHOD THEREOF TEIJIN PHARMA LTD 2007-06-14 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090299074-A1 BENZO[b]THIOPHEN DERIVATIVES AND PROCESS FOR THEIR PRODUCTION CMA1, TPSB2, CTRB1 MAPT 2088/4885POLB 1436/4885ALDH1A1 1548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.